Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Consults On Disclosure Of Confidential Info On Approved Products

This article was originally published in Clinica

Executive Summary

Health Canada is seeking feedback on a draft guideline that explains how the health minister intends to use new discretionary powers to disclose confidential business information (CBI) about approved drugs and medical devices, without prior permission from affected companies, to help health researchers and practitioners in their work and to improve patient safety.

You may also be interested in...



Canada’s Plan To Proactively Release Device Clinical Data Draws Flak From US Medtech

US medtech industry association AdvaMed is concerned that Health Canada’s plan to proactively release certain clinical information in medical device applications could undercut innovation.

Pharma Has High Hopes Of Pilot On Simultaneous Advice From EU Countries

Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers. 

Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug

While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.

Topics

UsernamePublicRestriction

Register

MT103278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel